Last data update: Apr 29, 2024. (Total: 46658 publications since 2009)
Records 1-1 (of 1 Records) |
Query Trace: Krapinunaya I[original query] |
---|
Validation of a SARS-CoV-2 spike protein ELISA for use in contact investigations and serosurveillance.
Freeman B , Lester S , Mills L , Rasheed MAU , Moye S , Abiona O , Hutchinson GB , Morales-Betoulle M , Krapinunaya I , Gibbons A , Chiang CF , Cannon D , Klena J , Johnson JA , Owen SM , Graham BS , Corbett KS , Thornburg NJ . bioRxiv 2020 Since emergence of SARS-CoV-2 in late 2019, there has been a critical need to understand prevalence, transmission patterns, to calculate the burden of disease and case fatality rates. Molecular diagnostics, the gold standard for identifying viremic cases, are not ideal for determining true case counts and rates of asymptomatic infection. Serological detection of SARS-CoV-2 specific antibodies can contribute to filling these knowledge gaps. In this study, we describe optimization and validation of a SARS-CoV-2-specific-enzyme linked immunosorbent assay (ELISA) using the prefusion-stabilized form of the spike protein [1]. We performed receiver operator characteristic (ROC) analyses to define the specificities and sensitivities of the optimized assay and examined cross reactivity with immune sera from persons confirmed tohave had infections with other coronaviruses. These assays will be used to perform contact investigations and to conduct large-scale, cross sectional surveillance to define disease burden in the population. |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 29, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure